Health Trials

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

ConditionMyotonic Dystrophy Type 1 (DM1)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-64
SponsorVertex Pharmaceuticals Incorporated

About this trial

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • VX-670
  • Placebo

Treatment groups

52 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Vertex Pharmaceuticals Incorporated

Lead sponsor

Source ClinicalTrials.gov